| Antibody resistance of SARS-CoV-2 variants B. 1.351 and B. 1.1. 7 P Wang, MS Nair, L Liu, S Iketani, Y Luo, Y Guo, M Wang, J Yu, B Zhang, ... Nature 593 (7857), 130-135, 2021 | 2250 | 2021 |
| Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike L Liu, P Wang, MS Nair, J Yu, M Rapp, Q Wang, Y Luo, JFW Chan, V Sahi, ... Nature 584 (7821), 450-456, 2020 | 1399 | 2020 |
| Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2 L Liu, S Iketani, Y Guo, JFW Chan, M Wang, L Liu, Y Luo, H Chu, Y Huang, ... Nature 602 (7898), 676-681, 2022 | 1160 | 2022 |
| Increased resistance of SARS-CoV-2 variant P. 1 to antibody neutralization P Wang, RG Casner, MS Nair, M Wang, J Yu, G Cerutti, L Liu, PD Kwong, ... Cell host & microbe 29 (5), 747-751. e4, 2021 | 940 | 2021 |
| Antibody evasion by SARS-CoV-2 Omicron subvariants BA. 2.12. 1, BA. 4 and BA. 5 Q Wang, Y Guo, S Iketani, MS Nair, Z Li, H Mohri, M Wang, J Yu, ... Nature 608 (7923), 603-608, 2022 | 634 | 2022 |
| Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite G Cerutti, Y Guo, T Zhou, J Gorman, M Lee, M Rapp, ER Reddem, J Yu, ... Cell host & microbe 29 (5), 819-833. e7, 2021 | 461 | 2021 |
| Nanobodies from camelid mice and llamas neutralize SARS-CoV-2 variants J Xu, K Xu, S Jung, A Conte, J Lieberman, F Muecksch, JCC Lorenzi, ... Nature 595 (7866), 278-282, 2021 | 166 | 2021 |
| A novel and expanding SARS-CoV-2 variant, B. 1.526, identified in New York MK Annavajhala, H Mohri, P Wang, M Nair, JE Zucker, Z Sheng, ... MedRxiv, 2021.02. 23.21252259, 2021 | 165* | 2021 |
| Defining the risk of SARS-CoV-2 variants on immune protection MM DeGrace, E Ghedin, MB Frieman, F Krammer, A Grifoni, A Alisoltani, ... Nature 605 (7911), 640-652, 2022 | 136 | 2022 |
| SARS-CoV-2 neutralizing antibody responses are more robust in patients with severe disease P Wang, L Liu, MS Nair, MT Yin, Y Luo, Q Wang, T Yuan, K Mori, AG Solis, ... Emerging microbes & infections 9 (1), 2091-2093, 2020 | 135 | 2020 |
| Artemisia annua L. extracts inhibit the in vitro replication of SARS-CoV-2 and two of its variants MS Nair, Y Huang, DA Fidock, SJ Polyak, J Wagoner, MJ Towler, ... Journal of ethnopharmacology 274, 114016, 2021 | 118 | 2021 |
| Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors S Iketani, F Forouhar, H Liu, SJ Hong, FY Lin, MS Nair, A Zask, Y Huang, ... Nature communications 12 (1), 2016, 2021 | 99 | 2021 |
| A SARS-CoV-2 ferritin nanoparticle vaccine elicits protective immune responses in nonhuman primates MG Joyce, HAD King, I Elakhal-Naouar, A Ahmed, KK Peachman, ... Science translational medicine 14 (632), eabi5735, 2021 | 98 | 2021 |
| Increased resistance of SARS-CoV-2 variants B. 1.351 and B. 1.1. 7 to antibody neutralization D Ho, P Wang, L Liu, S Iketani, Y Luo, Y Guo, M Wang, J Yu, B Zhang, ... | 97 | 2021 |
| Emergence and expansion of SARS-CoV-2 B. 1.526 after identification in New York MK Annavajhala, H Mohri, P Wang, M Nair, JE Zucker, Z Sheng, ... Nature 597 (7878), 703-708, 2021 | 90 | 2021 |
| Antigenicity and receptor affinity of SARS-CoV-2 BA. 2.86 spike Q Wang, Y Guo, L Liu, LT Schwanz, Z Li, MS Nair, J Ho, RM Zhang, ... Nature 624 (7992), 639-644, 2023 | 68 | 2023 |
| Quantifying the impact of immune history and variant on SARS-CoV-2 viral kinetics and infection rebound: A retrospective cohort study JA Hay, SM Kissler, JR Fauver, C Mack, CG Tai, RM Samant, S Connolly, ... Elife 11, e81849, 2022 | 68 | 2022 |
| Efficacy and breadth of adjuvanted SARS-CoV-2 receptor-binding domain nanoparticle vaccine in macaques HAD King, MG Joyce, I Lakhal-Naouar, A Ahmed, CM Cincotta, C Subra, ... Proceedings of the National Academy of Sciences 118 (38), e2106433118, 2021 | 56 | 2021 |
| Development of optimized drug-like small molecule inhibitors of the SARS-CoV-2 3CL protease for treatment of COVID-19 H Liu, S Iketani, A Zask, N Khanizeman, E Bednarova, F Forouhar, ... Nature communications 13 (1), 1891, 2022 | 54 | 2022 |
| Neutralizing antibody 5-7 defines a distinct site of vulnerability in SARS-CoV-2 spike N-terminal domain G Cerutti, Y Guo, P Wang, MS Nair, M Wang, Y Huang, J Yu, L Liu, ... Cell reports 37 (5), 2021 | 50 | 2021 |
zizhang shengColumbia universityDirección de correo verificada de columbia.edu
